论文部分内容阅读
目的:观察艾迪注射液联合射频消融术治疗原发性肝癌的疗效、不良反应及其对机体免疫功能等的影响。方法:68例原发性肝癌患者分为治疗组和对照组,对照组给予单纯射频消融治疗,治疗组在射频治疗同时给予艾迪注射液治疗。结果:治疗组及对照组总有效率分别为70.58%和55.88%(P<0.01)。两组治疗后丙氨酸转氨酶(ALT)、谷草转氨酶(AST)较治疗前下降(P<0.05);两组治疗前后总胆红素(T-BIL)及血清白蛋白(ALB)水平无明显变化。治疗组CD4细胞亚群和CD4/CD8比例治疗后较治疗前增高(P<0.05);而单纯射频组CD4细胞亚群和CD4/CD8比例无明显变化。在不良反应方面,消化道反应治疗组显著轻于对照组(P<0.01);两组骨髓抑制差异不明显(P>0.05)。结论:艾迪注射液联合射频消融治疗原发性肝癌可增强疗效,减轻射频消融对肝功能损害。
Objective: To observe the curative effect, adverse reaction and its effect on the immune function of AID patients treated with Aidi injection combined with radiofrequency catheter ablation. Methods: Sixty-eight patients with primary liver cancer were divided into treatment group and control group. The control group received radiofrequency catheter ablation alone. The treatment group was treated with Aidi injection simultaneously with radiofrequency ablation. Results: The total effective rate of the treatment group and the control group were 70.58% and 55.88% (P <0.01). The levels of ALT and AST in both groups decreased after treatment (P <0.05). There was no significant difference in total bilirubin (T-BIL) and serum albumin (ALB) between the two groups before and after treatment Variety. The CD4 cell subsets and the ratio of CD4 / CD8 in the treatment group were significantly higher than those before treatment (P <0.05), while the CD4 cell subsets and CD4 / CD8 ratio in the radiotherapy group had no significant changes. Adverse reactions, digestive tract response was significantly lighter than the control group (P <0.01); bone marrow suppression was no significant difference between the two groups (P> 0.05). Conclusion: Aidi injection combined with radiofrequency ablation in the treatment of primary liver cancer can enhance the curative effect and reduce the damage to liver function caused by radiofrequency ablation.